Business
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab dosesWeight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantageStrong safety and tolerability profile maintained — no
About this update from Skye Bioscience, Inc.
[{"type":"image","alt":"Skye Bioscience, Inc.","displaySize":"","headline":null,"caption":"Skye Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":141,"url":"https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7pwAl2G8ZGCyG39CbcNdmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c","width":300,"height":141}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab doses","length":210,"tagName":"p"}]},{"val":[{"type":"text","content":"Weight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantage","length":236,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong safety and tolerability profile maintained — no serious adverse events or adverse events of special interest reported during the 52-week extension period","length":160,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":606,"olType":false},{"type":"text","content":"SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond™ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody.","length":433,"tagName":"p"},{"type":"text","content":"CBeyond Extension Study Design and Interim Data Summary","length":55,"tagName":"p"},{"type":"text","content":"The blinded extension of the CBeyond study for combination cohorts was opened in May 2025 for participants assigned to either nimacimab plus semaglutide or placebo plus semaglutide arms. Eligible patients completed 26 weeks of treatment and were precluded from being off therapy for longer than 4 weeks. In total, 19 participants in the combina...